Back to Search
YAZAN ALSAYED, MD
MD
Hematology & Oncology Physician
NPI: 1558460626IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
ME110878(FL)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
OTHER
Class of 1989
Research & Publications (20)
Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.
PMID 19389881·Blood·2009
8-other
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.
PMID 19515721·Blood·2009
3-trial
Proteomics analysis in post-transplant lymphoproliferative disorders.
PMID 18573174·Eur J Haematol·2008
8-other
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.
PMID 18492953·Blood·2008
3-trial
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma.
PMID 18470907·Cancer·2008
8-other
Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment.
PMID 18245550·Clin Cancer Res·2008
8-other
Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.
PMID 17895401·Blood·2008
8-other
Sentinel lymph node biopsy (SLNB) in management of N0 stage T1-T2 lip cancer as a "same day" procedure.
PMID 17936674·Oral Oncol·2008
8-other
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.
PMID 18669874·Blood·2008
3-trial
Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.
PMID 17489983·Br J Haematol·2007
8-other
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling.
PMID 18056185·Clin Cancer Res·2007
3-trial
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
PMID 17593024·Br J Haematol·2007
3-trial
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
PMID 17416735·Blood·2007
3-trial
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.
PMID 17284528·Blood·2007
8-other
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.
PMID 17119115·Blood·2007
7-preclinical
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.
PMID 17105813·Blood·2007
8-other
Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
PMID 17121904·Clin Cancer Res·2006
8-other
Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid.
PMID 11060298·J Biol Chem·2001
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1545 AIRPORT BLVD, SUITE 2000
PENSACOLA, FL 32504 - Phone
- (850) 474-8382
Quick Facts
- NPI
- 1558460626
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 37
- Publications
- 20
Are you this provider?
Claim Your Profile